ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals
Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals and sales. But a group of Harvard researchers has found another way to measure the impact individual drugmakers have had in …